Detailed Narrative
PROSEEK Study Outcomes and Strategic Re-evaluation
SPARC announced the full results of its PROSEEK study, which involved 491 patients, confirming the negative trends observed in the interim analysis. The long-term extension study with approximately 100 patients was also discontinued. This outcome prompted a significant strategic re-evaluation, leading the company to pivot its focus and optimize its portfolio towards more promising assets and a flexible business model.
Portfolio Optimization: Anchor Assets SCD-153 and SBO-154
The company is narrowing its therapeutic area focus, designating SCD-153 and SBO-154 as anchor assets. Neurodegenerative disease programs, except for a few early platforms, have been parked due to challenges with animal models and clinical trial designs. The new focus areas are Oncology, emphasizing smart drug delivery and synthetic lethality, and Immunology, targeting safe topical alternatives for autoimmune conditions.
SCD-153 Program for Alopecia Areata Advances
SCD-153, a topical pro-drug for autoimmune disorders like Alopecia Areata, has successfully completed its 'first in human' single ascending dose study, showing good tolerability up to the highest dose with no dose-limiting toxicities. Preclinical data demonstrated hair growth and reduction of CD8+ T cells in animal models. A Phase 1B study in Alopecia Areata patients in India is slated to begin in Q1 FY26, with an interim readout expected in Q1 FY27 and a global Phase IIB study targeted for Q4 FY27.
SBO-154: A Novel MUC-1 ADC in Oncology
SBO-154 is a first-in-class humanized IgG1 antibody drug conjugate targeting the novel SEA domain of MUC-1, designed for advanced solid tumors. Preclinical studies showed high potency in MUC1-expressing cell lines and significant tumor reduction in xenograft models. Preliminary toxicology studies in cynomolgus monkeys demonstrated good tolerability up to 6 mg/Kg. SPARC anticipates filing the IND by the end of Q4 FY2025, with Phase I study initiation in Q1 FY26, targeting ER+ breast, lung, and ovarian cancers.
Pursuit of Short-Term Cash Catalysts
To address resource constraints, SPARC is aggressively pursuing several short-term cash-generating opportunities. This includes seeking a Pediatric Rare Disease Voucher for Sezaby, potentially valued over 150 million USD, with a court opinion expected in Q4 FY25. The company is also working to enforce Sezaby's 7-year orphan drug exclusivity by Q3 FY25 and aims to identify a development and commercialization partner for Vodobatinib's CML program by the end of FY25.
Resource Management and Operational Adjustments
SPARC initiated the year with 15.2 million USD in opening cash and is currently relying on operating cash flow and approved debt limits, which are projected to sustain operations until mid-Q1 next year. The company has undertaken significant headcount reductions, with current staff at 324 against a planned FY2025 headcount of over 400, and US headcount decreasing from 37 to 7, reflecting a strategic down-sizing of clinical development capabilities.
SCO-155 Partnership and New Business Model
SPARC has adopted a more flexible business model, exemplified by the formation of Tiller Therapeutics, a NewCo with UCSF, for the SCO-155 program. SPARC will receive 55% of Tiller's initial shares. SCO-155, a PSMA-targeted small molecule drug conjugate, demonstrated strong in vitro efficacy and complete tumor regression in an in vivo xenograft model, paving the way for IND-enabling studies. This partnership model allows SPARC to advance promising programs without committing extensive internal resources.